Moderna Q1 Sales Tripled to $389M, Loss Narrows to $3.40, EU OKs mCOMBRIAX
Moderna reported Q1 revenue of $389 million, more than triple year-earlier levels, driven by 80% international sales and a U.K. COVID booster agreement. Adjusted loss narrowed to $3.40 per share despite a $900 million litigation charge, while EU approved mCOMBRIAX flu-COVID combo and launched a Phase III lung cancer trial.
1. Q1 Financial Performance
Revenue reached $389 million in Q1, up more than 200% from a year earlier, driven by strong international demand. Adjusted loss narrowed to $3.40 per share and adjusted cash costs fell 26% year-over-year through financial discipline.
2. Product Approvals and Pipeline
European regulators approved mCOMBRIAX, the combined influenza and COVID-19 vaccine for adults 50 and older, marking Moderna's fourth approved product. Oncology efforts advanced with the launch of a Phase III trial for Intismeran as a monotherapy in Stage 1 lung cancer.
3. International Sales and Partnerships
International markets accounted for 80% of Q1 revenue, underpinned by a new long-term COVID booster contract with the U.K. government. Moderna also expanded government partnerships in Canada and Australia to secure future booster campaigns.
4. Legal Charge and Guidance
A $900 million litigation settlement charge weighed on quarterly results but did not alter the company's guidance. Moderna reaffirmed plans for up to 10% revenue growth in 2026 and aims to achieve break-even by 2028.